Phase 3 N=29 A Randomized, Placebo-controlled, Tourette Syndrome Study.
Tourette Syndrome
Primary: Change From Baseline in Total Tic Score at Day 70 — -5.0; -14.29 units on a scale — p=0.0259
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
Tourette Syndrome
Primary: Change in TTS — -14.29 units on a scale
Phase 3 N=1,249 The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Colorectal Cancer
Primary: To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the…
Phase 3 N=83 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Dyskinesia · Levodopa Induced Dyskinesia · Parkinson's Disease
Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8 — -6.7; -12.3; -17.9; -16.7 units on a scale — p=0.0051
Phase 3 N=333 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 97.8; 90.1 percentage of participants
Phase 3 N=46 Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
Cystic Fibrosis · Advanced Lung Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 43; 18 Participants
Phase 3 N=1,233 Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 26: Excluding Rescue Approach — -1.02; -1.08; -1.05; -1.49 Percentage — p=<0.001
Phase 3 N=1,579 Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Disease-specific Survival (DSS) (10-year Rates Reported) — 95; 96 percentage of participants — p=0.45
Phase 3 N=20 Long-term Study of FK949E in Elderly Bipolar Disorder Patients
Bipolar Disorder · Elderly
Primary: Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -13.1 units on a scale
Phase 3 N=37 A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Number of Microscopically Confirmed Episodes of Infusion Set Occlusions — 0; 0 Episodes
Phase 3 N=13,885 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
Peripheral Artery Disease
Primary: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke — 751; 740 Participants — p=0.650
Phase 3 N=128 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Iron Deficiency Anaemia · Inflammatory Bowel Disease · Crohn's Disease
Primary: Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS) — 2.26; 0.01 g/dL — p=< 0.0001
Phase 3 N=650 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.5; 100 percentage of participants
Phase 3 N=357 Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes — 2.69; 0.03; 3.44; 0.03 μg/mL
Phase 3 N=370 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle — 53; 44; 26; 31 participants